Claims
- 1. Compounds corresponding to the formula ##STR45## in which R.sub.1 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl group or a phenyl, benzyl, C.sub.3 to C.sub.7 cycloalkyl, C.sub.7 to C.sub.12 polycycloalkyl, dibenzocycloalkyl, dibenzo-oxepine, dibenzoazepine, dibenzothiepine, benzopyrrolocycloalkyl, benzothienocycloalkyl or naphthyl group, optionally substituted by one or a number of substituents chosen from halogen atoms, the trifluoromethyl group, and C.sub.1 to C.sub.6 alkyl, aryl, acyl, alkoxy and alkylthio radicals,
- Z represents C.dbd.O, SO.sub.2 or (CH.sub.2).sub.n in which n is between 0 and 5,
- R.sub.2 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl group or a phenyl, benzyl, cycloalkyl, pyrrole, furan, pyridinyl or thioophenyl group, optionally substituted by one or a number of substituents chosen from halogen atoms and C.sub.1 to C.sub.6 alkyl, aryl, acyl, alkoxy and alkylthio groups,
- R'.sub.2 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl group or a phenyl group,
- R.sub.3 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl group or a benzyl or phenethyl group,
- R.sub.4 represents a hydrogen, chlorine, fluorine, or bromine atom or a linear or branched C.sub.1 to C.sub.6 alkyl group,
- R.sub.5 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl group or a benzyl or phenethyl group,
- R.sub.6 represents a hydrogen atom, a linear or branched C.sub.1 to C.sub.6 alkyl group, COR,.sub.7, CO.sub.2 R.sub.7, or CONHR.sub.7, in which R.sub.7 represents a linear or branched C.sub.1 to C.sub.6 alkyl group, or a variously substituted phenyl group, their salts, or solvates thereof.
- 2. A compound according to claim 1, wherein R.sub.1 represents a phenyl group or a naphthyl optionally substituted by one or a number of substituents chosen from halogen atoms and C.sub.1 to C.sub.6 alkyl, aryl, acyl, alkoxy or alkylthio.
- 3. A compound according to claim 1, wherein R.sub.1 represents a dibenzothiepine.
- 4. A compound according to claim 1, wherein Z represents CO.
- 5. A compound according to claim 1, wherein Z represents SO.sub.2.
- 6. A compound according to claim 1, wherein Z represents (CH.sub.2).sub.n in which n is between 1 and 5.
- 7. A compound according to claim 1, wherein R.sub.2 and R'.sub.2 represent a hydrogen.
- 8. A compound according to claim 1, wherein R.sub.2 represents a hydrogen.
- 9. A compound according to claim 1, wherein R.sub.2 represents a methyl.
- 10. A compound according to claim 1, wherein R.sub.2 represents a phenyl group optionally substituted by one or a number of substituents chosen from halogen atoms and alkyl, aryl, acyl, alkoxy or alkylthio groups.
- 11. A compound according to claim 1, wherein R.sub.3 represents a hydrogen.
- 12. A compound according to claim 1, wherein R.sub.4 represents a hydrogen.
- 13. A compound according to claim 1, wherein R.sub.5 and R.sub.6 represent a hydrogen.
- 14. A compound according to claim 1, wherein R.sub.5 is a linear or branched alkyl group.
- 15. A compound according to claim 1, wherein R.sub.5 and R.sub.6 represent a linear or branched alkyl group.
- 16. A compound according to claim 1, in the form of a hydrochloride, hydrobromide, sulfate, fumarate or maleate salt.
- 17. A process for the preparation of the compound of claim 1 comprising reacting a compound of formula (II): ##STR46## in which R.sub.1, Z, R.sub.2 and R'.sub.2 have the meanings in claim 1 and where X is defined as a leaving group selected from the group consisting of a halogen where the halogen is selected from the group consisting of: bromine, iodine and chlorine, a mesylate, a tosylate and a triflate, with a compound of formula (III): ##STR47## in which R.sub.3, R.sub.4, R.sub.5 and R.sub.6 having the meaning indicated in claim 1 and R.sub.6 is other than a hydrogen atom.
- 18. A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 1 in combination with an acceptable pharmaceutical vehicle.
- 19. A method of treating depression, anxiety, migraine, or vasospastic disorders, the method comprising administering to the patient an effective amount of at least one compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
92 15919 |
Dec 1992 |
FRX |
|
Government Interests
This is a National Stage filing under 35 U.S.C. .sctn.371 of PCT/FR93/01317, filed Dec. 29, 1993, published as WO94/15916, Jul. 21, 1994.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/FR93/01317 |
12/29/1993 |
|
|
6/29/1995 |
6/29/1995 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO94/15916 |
7/21/1994 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3929793 |
Popelak et al. |
Dec 1975 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0 457 701 |
May 1991 |
EPX |
2 082 175 |
Mar 1982 |
GBX |
Non-Patent Literature Citations (1)
Entry |
M.J. Millan, S 14671: A Naphtylpiperazine 5HT Angonist, Journal of Pharmacology and Experimental Therapeutics, vol. 262 (2), pp. 451-463. |